Biological interaction betwen anti-epidermal growth factor receptor agent cetuximab and magnesium

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 8, 2008, Pages 1267-1269

  Vincenzi, Bruno ^a   Santini, Daniele ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Cetuximab; Colorectal cancer; Magnesium

Indexed keywords

CETUXIMAB; ELECTROLYTE; EPIDERMAL GROWTH FACTOR RECEPTOR; MAGNESIUM; PROTEIN P21; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; TRANSIENT RECEPTOR POTENTIAL CHANNEL M6; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CARCINOMA; EDITORIAL; ENDOTHELIUM CELL; GENE MUTATION; GENETIC POLYMORPHISM; HOMEOSTASIS; HUMAN; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; MAGNESIUM EXCRETION; MAGNESIUM HOMEOSTASIS; MEDLINE; PAPULE; PUSTULE; SIDE EFFECT; SIGNAL TRANSDUCTION; UPREGULATION; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; KIDNEY; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; HOMEOSTASIS; HUMANS; KIDNEY; MAGNESIUM; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 45549092390     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.8.1267     Document Type: Editorial

References (18)

1. Dai LJ, Ritchie G, Kerstan D, et al. Magnesium transport in the renal distal convoluted tubule. Physiol Rev 2001;81:51-84
2. 2+ transport. Rev Physiol Biochem Pharmacol 2007;158:77-160
3. Agus ZS. Hypomagnesemia. J Am Soc Nephrol 1999;10:1616-22
4. 2+ channels in health and disease. J Am Soc Nephrol 2005; 16:15-26
5. 2+ absorption. J Biol Chem 2004;279:19-25
6. + channel, ROMK. Nat Genet 1996;14:152-6
7. +-ATPase gamma-subunit. Ann NY Acad Sci 2003; 986:437-43
8. Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002;31:166-70
9. Walder RY, Landau D, Meyer P, et al. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 2002;31:171-4
10. Groenestege WM, Thebault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesaemia. J Clin Invest 2007;117:2260-7
11. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005;97:1221-4
12. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007;8:387-94
13. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8
14. Saltz L, Kies M, Abbruzzese JL, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003;22:204
15. Vincenzi B, Santini D, Russo A, et al. Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann Oncol 2006;17:835-41
16. Wolf FI, Maier JA, Nasulewicz A, et al. Magnesium and neoplasia: from carcinogenesis to tumor growth and progression or treatment. Arch Biochem Biophys 2007;458:24-32
17. Bernardini D, Nasulewicz A, Mazur A, Maier JA. Magnesium and microvasculatur endothelial cells: a role in inflammation and angiogenesis. Front Biosci 2005;10:1177-82
18. ++-induced endothelial cell migration: substratum selectivity and receptor-involvement. Angiogenesis 2001;4:21-8